Genetic Variation in IL28B: Impact on Drug Development for Chronic Hepatitis C Infection

As more pharmacogenomic insights into diseases and their treatments and toxicities are published each year, the challenge arises to incorporate such insights into clinical practice and drug development. 1 For instance, recent genomic discoveries related to hepatitis C offer a challenge to clinicians...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2010-11, Vol.88 (5), p.708-711
Main Authors: Clark, P J, Thompson, A J V, McHutchison, J G
Format: Article
Language:English
Subjects:
Antiviral Agents - administration & dosage
Antiviral Agents - chemistry
Antiviral Agents - therapeutic use
Biological and medical sciences
Drug Administration Schedule
Drug Discovery
Genotype
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - genetics
Hepatitis C, Chronic - immunology
Human viral diseases
Humans
Infectious diseases
Interferons
Interleukins - genetics
Medical sciences
Pharmacology. Drug treatments
Phenotype
Polymorphism, Single Nucleotide
Translational Research, Biomedical
Viral diseases
Viral hepatitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:As more pharmacogenomic insights into diseases and their treatments and toxicities are published each year, the challenge arises to incorporate such insights into clinical practice and drug development. 1 For instance, recent genomic discoveries related to hepatitis C offer a challenge to clinicians, researchers, and health administrators to translate this information into knowledge in order to develop safer and more effective therapeutic strategies for all patients. Clinical Pharmacology & Therapeutics (2010) 88 5, 708–711. doi: 10.1038/clpt.2010.185
ISSN:0009-9236
1532-6535
DOI:10.1038/clpt.2010.185